8-K: ChromaDex Reports Strong Q3 2024 Results with 31% Revenue Growth and Record Profitability

ChromaDex announced a strong third quarter with a 31% increase in revenue, record net income, and significant growth in Niagen ingredient sales.

Summary

• ChromaDex reported a 31% year-over-year increase in net sales, reaching $25.6 million for the third quarter of 2024.
• The company achieved a gross margin of 63.5%, a 210 basis point improvement compared to the same quarter last year.
• Net income reached a record $1.9 million, or $0.02 per share, a significant improvement from a net loss of $1.0 million in the prior year quarter.
• Adjusted EBITDA also reached a record of $2.9 million, up from $0.5 million in the third quarter of 2023.
• Niagen ingredient sales, including both food-grade and pharmaceutical-grade, saw a substantial increase of 368% year-over-year, reaching $6.7 million.
• The company expanded the availability of its Niagen+ product line to over 100 wellness clinics as of October 31, 2024.
• ChromaDex is projecting approximately 15% revenue growth for the full year 2024.
• Operating cash flow has grown to $32.4 million.

Sentiment

Score: 9

Explanation: The document presents very positive financial results, with strong revenue growth, improved profitability, and a positive outlook. The expansion into new markets and the focus on scientific research further enhance the positive sentiment.

Positives

• The company experienced significant revenue growth, driven by both Tru Niagen and Niagen ingredient sales.
• Gross margins improved, indicating better cost management and product mix.
• The company achieved record net income and Adjusted EBITDA, demonstrating improved profitability.
• Sales and marketing expenses became more efficient as a percentage of net sales.
• The expansion of Niagen+ to more wellness clinics indicates a growing market for pharmaceutical-grade Niagen.
• The company has a strong cash position with $32.4 million in operating cash and no debt.
• The company is projecting approximately 15% revenue growth for the full year 2024.

Negatives

• Operating expenses increased by 12%, driven by higher sales and marketing and general and administrative expenses.
• Cash flows from operating activities decreased by $2.9 million for the nine months ended September 30, 2024, compared to the prior year.

Risks

• The company faces risks related to inflationary and adverse economic conditions.
• There are risks associated with reliance on a single or limited number of third-party suppliers.
• The company faces risks related to conducting business in China.
• There are risks related to securing adequate quantities of pharmaceutical-grade Niagen.
• The company faces risks related to obtaining contracts with U.S. FDA-registered 503B outsourcing facilities.
• There are risks related to maintaining intellectual property and obtaining new patents.
• Clinical trials may be unsuccessful or insufficient to meet regulatory standards.
• The company faces risks related to determinations made by the FDA and other governmental authorities.

Future Outlook

ChromaDex expects approximately 15% revenue growth for the full year 2024, driven by e-commerce, established partnerships, and the Niagen+ product line. Gross margin is projected to improve slightly year-over-year. Selling and marketing expenses are expected to increase in absolute dollars but remain stable as a percentage of net sales. General and administrative expenses are expected to be down approximately $1.5 million year-over-year.

Management Comments

• ChromaDex CEO Rob Fried stated that the company achieved its best quarter to date with $25.6 million in revenue, a 31% increase year-over-year, supported by a strong gross margin of 63.5%, record-setting net income of $1.9 million, and healthy cash flows.
• He also mentioned that this quarter marks the first sales of Niagen+ products and they look forward to further extending their availability to more wellness clinics.

Industry Context

The results indicate a growing market for NAD+ precursors and a successful expansion into the pharmaceutical-grade market with Niagen+. The company's focus on scientific research and clinical trials positions it well in the health and wellness industry. The expansion into wellness clinics is a strategic move to reach a new customer base.

Comparison to Industry Standards

• ChromaDex's 31% revenue growth in Q3 2024 is strong compared to the broader dietary supplement industry, which typically sees single-digit growth rates.
• The company's gross margin of 63.5% is competitive within the nutraceutical sector, where margins can vary widely based on product type and distribution channels.
• The significant increase in Niagen ingredient sales, particularly the 368% growth year-over-year, suggests a successful strategy in supplying raw materials to other manufacturers, which is a key differentiator compared to companies focused solely on direct-to-consumer sales.
• Compared to companies like Herbalife and Amway, which have large direct sales networks, ChromaDex's focus on e-commerce and partnerships with retailers like Watsons provides a different approach to market penetration.
• The expansion into pharmaceutical-grade Niagen and the pursuit of an IND application for Ataxia Telangiectasia sets ChromaDex apart from many other supplement companies, positioning it more like a biotech company.

Legal Proceedings

• The company incurred higher legal expenses to support the Niagen+ launch and litigation matters.

Related Party Transactions

• The company has trade receivables from a related party of $2.0 million and $2.8 million as of September 30, 2024 and December 31, 2023 respectively.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and positive outlook.
• Employees may benefit from the company's growth and success.
• Customers will have access to innovative health solutions.
• Suppliers may see increased demand for their products.
• Creditors will have increased confidence in the company's financial stability.

Next Steps

• The company plans to continue expanding the availability of Niagen+ to more wellness clinics.
• ChromaDex will continue to invest in research and development to drive future innovation.
• The company will continue to make focused investments to drive brand awareness and support new market launches.
• ChromaDex is working to schedule meetings with the FDA as part of the Companys efforts to pursue an Investigational New Drug (IND) application for the use of nicotinamide riboside (NR) in the treatment of Ataxia Telangiectasia (AT).

Key Dates

Keywords

ChromaDex, Niagen, nicotinamide riboside, NAD+, Tru Niagen, financial results, revenue growth, EBITDA, pharmaceutical-grade, wellness clinics, clinical trials